Virtual Meeting: 2021 ASCO Annual Meeting: Jun 4, 2021 – Jun 8, 2021
- Conferences
- Dec 1, 2021
- 3 min read
Updated: Feb 21, 2024
2021 ASCO Annual Meeting: Jun 4, 2021 – Jun 8, 2021 Chicago, IL
2021 ASCO Annual Meeting: Jun 4, 2021 – Jun 8, 2021
Learn more:
Session: Hematologic Malignancies—Plasma Cell Dyscrasia
Oral Abstract Session
Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM). https://meetinglibrary.asco.org/record/195429/abstract
Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial. https://meetinglibrary.asco.org/record/195431/abstract
Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients. https://meetinglibrary.asco.org/record/196624/abstract
Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. https://meetinglibrary.asco.org/record/195436/abstract
Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. https://meetinglibrary.asco.org/record/195428/abstract
Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. https://meetinglibrary.asco.org/record/195437/abstract
Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). https://meetinglibrary.asco.org/record/195434/abstract
Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). https://meetinglibrary.asco.org/record/195433/abstract
Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). https://meetinglibrary.asco.org/record/195432/abstract
Hematologic Malignancies—Plasma Cell Dyscrasia
Hematologic Malignancies
Poster Discussion Session
MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial. https://meetinglibrary.asco.org/record/196625/abstract
Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial. https://meetinglibrary.asco.org/record/195522/abstract
Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM). https://meetinglibrary.asco.org/record/195466/abstract
Prospective comparison of whole body MRI and FDG PET/CT for detection of multiple myeloma and correlation with markers of disease burden: Results of the iTIMM trial. https://meetinglibrary.asco.org/record/195462/abstract
CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy. https://meetinglibrary.asco.org/record/195446/abstract
Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted FasT CAR-T GC012F for patients with relapsed/refractory multiple myeloma. https://meetinglibrary.asco.org/record/195484/abstract
Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma. https://meetinglibrary.asco.org/record/195469/abstract
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. https://meetinglibrary.asco.org/record/195486/abstract
Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM). https://meetinglibrary.asco.org/record/195450/abstract
Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM). https://meetinglibrary.asco.org/record/195449/abstract
Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study. https://meetinglibrary.asco.org/record/195458/abstract
Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial. https://meetinglibrary.asco.org/record/195791/abstract
Poster Session
